LINC01818

Across TCGA pan-cancer cohorts, LINC01818 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LINC01818’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC01818 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01818 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, CHOL, and UCEC are the cancer types where LINC01818 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01818 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−1.284	<.001	9	view →
CHOL	All	All	−1.588	<.001	5	view →
UCEC	All	IV	+0.495	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LINC01818–LIHC

Open the LIHC breakdown →